Rocklatan®
Netarsudil/Latanoprost is a fixed-dose combination targeting both conventional and uveoscleral outflow pathways for IOP reduction.
| Dosage Form | Ophthalmic Solution |
| Strength | 0.02% / 0.005% |
| Storage | Store at 2–8°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Open-angle glaucoma; ocular hypertension (IOP reduction).
Combines ROCK/NET inhibition (netarsudil) increasing trabecular outflow with prostaglandin F2α analog (latanoprost) increasing uveoscleral outflow, providing complementary IOP reduction.
Each Burrard Pharmaceuticals technology transfer package for Netarsudil / Latanoprost includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.